Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials.
Drexel H, Rosano GMC, Lewis BS, Huber K, Vonbank A, Dopheide JF, Mader A, Niessner A, Savarese G, Wassmann S, Agewall S. Drexel H, et al. Among authors: mader a. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 1;6(2):97-103. doi: 10.1093/ehjcvp/pvz029. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 31298686 Free article. Review.
Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
Tripolt NJ, Kolesnik E, Pferschy PN, Verheyen N, Ablasser K, Sailer S, Alber H, Berger R, Kaulfersch C, Leitner K, Lichtenauer M, Mader A, Moertl D, Oulhaj A, Reiter C, Rieder T, Saely CH, Siller-Matula J, Weidinger F, Zechner PM, von Lewinski D, Sourij H; EMMY study group. Tripolt NJ, et al. Among authors: mader a. Am Heart J. 2020 Mar;221:39-47. doi: 10.1016/j.ahj.2019.12.004. Epub 2019 Dec 12. Am Heart J. 2020. PMID: 31901799
The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials.
Drexel H, Lewis BS, Rosano GMC, Saely CH, Tautermann G, Huber K, Dopheide JF, Kaski JC, Mader A, Niessner A, Savarese G, Schmidt TA, Semb A, Tamargo J, Wassmann S, Per Kjeldsen K, Agewall S, Pocock SJ. Drexel H, et al. Among authors: mader a. Eur Heart J Cardiovasc Pharmacother. 2021 Sep 21;7(5):453-459. doi: 10.1093/ehjcvp/pvaa126. Eur Heart J Cardiovasc Pharmacother. 2021. PMID: 33135079 Review.
Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy.
Drexel H, Pocock SJ, Lewis BS, Saely CH, Kaski JC, Rosano GMC, Tautermann G, Huber K, Dopheide JF, Mader A, Niessner A, Savarese G, Schmidt TA, Semb AG, Tamargo J, Wassmann S, Clodi M, Kjeldsen KP, Agewall S. Drexel H, et al. Among authors: mader a. Eur Heart J Cardiovasc Pharmacother. 2022 May 5;8(3):302-310. doi: 10.1093/ehjcvp/pvab048. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 34180504 Review. No abstract available.
148 results